View in EDS

Emapalumab for Maladaptive Interferon-γ-Mediated Inflammation in Drug Reaction With Eosinophilia and Systemic Symptoms Complicating First-Line Antituberculosis Therapy.

Saved in:
Bibliographic Details
Title: Emapalumab for Maladaptive Interferon-γ-Mediated Inflammation in Drug Reaction With Eosinophilia and Systemic Symptoms Complicating First-Line Antituberculosis Therapy.
Authors: Almodallal Y; Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Whitehurst D; Division of Infectious Diseases, Center for Inflammation and Tolerance, Cincinnati Children's Hospital Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Way SS; Division of Infectious Diseases, Center for Inflammation and Tolerance, Cincinnati Children's Hospital Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Koo J; Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA., Kumar AR; Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children's Medical Center, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.
Source: Pediatric blood & cancer [Pediatr Blood Cancer] 2025 Dec; Vol. 72 (12), pp. e32052. Date of Electronic Publication: 2025 Sep 16.
Publication Type: Letter
Journal Info: Publisher: John Wiley Country of Publication: United States NLM ID: 101186624 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1545-5017 (Electronic) Linking ISSN: 15455009 NLM ISO Abbreviation: Pediatr Blood Cancer Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1545-5017
DOI:10.1002/pbc.32052